Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Producti… Read more
Maravai Lifesciences Holdings Inc (MRVI) - Net Assets
Latest net assets as of September 2025: $431.86 Million USD
Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) has net assets worth $431.86 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($849.19 Million) and total liabilities ($417.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $431.86 Million |
| % of Total Assets | 50.86% |
| Annual Growth Rate | 25.45% |
| 5-Year Change | 273.0% |
| 10-Year Change | N/A |
| Growth Volatility | 96.28 |
Maravai Lifesciences Holdings Inc - Net Assets Trend (2018–2024)
This chart illustrates how Maravai Lifesciences Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Maravai Lifesciences Holdings Inc (2018–2024)
The table below shows the annual net assets of Maravai Lifesciences Holdings Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $577.21 Million | -26.92% |
| 2023-12-31 | $789.88 Million | -12.74% |
| 2022-12-31 | $905.24 Million | +65.99% |
| 2021-12-31 | $545.36 Million | +252.42% |
| 2020-12-31 | $154.75 Million | +7.00% |
| 2019-12-31 | $144.63 Million | -2.29% |
| 2018-12-31 | $148.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Maravai Lifesciences Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 17912800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $140.89 Million | 43.31% |
| Common Stock | $2.53 Million | 0.78% |
| Other Components | $181.87 Million | 55.91% |
| Total Equity | $325.29 Million | 100.00% |
Maravai Lifesciences Holdings Inc Competitors by Market Cap
The table below lists competitors of Maravai Lifesciences Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Banco Products (I) Limited
NSE:BANCOINDIA
|
$286.08 Million |
|
Pubmatic Inc
NASDAQ:PUBM
|
$286.11 Million |
|
Chengdu Huasun Group Inc Ltd
SHE:000790
|
$286.16 Million |
|
Nathans Famous Inc
NASDAQ:NATH
|
$286.17 Million |
|
Lenzing AG
LSE:0NCV
|
$285.86 Million |
|
Flinders Resources Limited
V:FDR
|
$285.86 Million |
|
Altri SGPS SA
LS:ALTR
|
$285.84 Million |
|
ShaoYang Victor Hydraulics Co.Ltd
SHE:301079
|
$285.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maravai Lifesciences Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 416,753,000 to 325,292,000, a change of -91,461,000 (-21.9%).
- Net loss of 144,846,000 reduced equity.
- Share repurchases of 2,081,999 reduced equity.
- Other factors increased equity by 55,466,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-144.85 Million | -44.53% |
| Share Repurchases | $2.08 Million | -0.64% |
| Other Changes | $55.47 Million | +17.05% |
| Total Change | $- | -21.95% |
Book Value vs Market Value Analysis
This analysis compares Maravai Lifesciences Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.92x to 1.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.62 | $3.12 | x |
| 2019-12-31 | $1.46 | $3.12 | x |
| 2020-12-31 | $0.92 | $3.12 | x |
| 2021-12-31 | $2.59 | $3.12 | x |
| 2022-12-31 | $4.14 | $3.12 | x |
| 2023-12-31 | $3.16 | $3.12 | x |
| 2024-12-31 | $2.36 | $3.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maravai Lifesciences Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -55.89%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 3.10x
- Recent ROE (-44.53%) is below the historical average (13.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -12.28% | -14.32% | 0.23x | 3.74x | $-32.17 Million |
| 2019 | -6.00% | -5.93% | 0.25x | 4.09x | $-22.63 Million |
| 2020 | 86.87% | 27.06% | 0.22x | 14.36x | $68.04 Million |
| 2021 | 57.70% | 22.78% | 0.42x | 6.08x | $150.49 Million |
| 2022 | 40.39% | 24.94% | 0.39x | 4.19x | $165.68 Million |
| 2023 | -28.56% | -41.19% | 0.19x | 3.57x | $-160.70 Million |
| 2024 | -44.53% | -55.89% | 0.26x | 3.10x | $-177.38 Million |
Industry Comparison
This section compares Maravai Lifesciences Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maravai Lifesciences Holdings Inc (MRVI) | $431.86 Million | -12.28% | 0.97x | $285.91 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |